

Piero Picci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6472280/publications.pdf>

Version: 2024-02-01

314
papers

22,283
citations

5574

82
h-index

12596

132
g-index

317
all docs

317
docs citations

317
times ranked

16741
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG/STS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	4.1	46
2	Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OSA-2). <i>Cancer</i> , 2022, 128, 1958-1966.	4.1	12
3	Extraskeletal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 1142-1150.	1.5	23
4	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	3.7	15
5	Neuroendocrine differentiation in a large series of genetically-confirmed Ewing's sarcoma family tumor: Does it provide any diagnostic or prognostic information?. <i>Pathology Research and Practice</i> , 2021, 219, 153362.	2.3	5
6	Cell Cycle Regulatory Protein Expression in Multinucleated Giant Cells of Giant Cell Tumor of Bone: do They Proliferate?. <i>Pathology and Oncology Research</i> , 2021, 27, 643146.	1.9	3
7	Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study. <i>Cancers</i> , 2021, 13, 2789.	3.7	1
8	Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study. <i>Cancers</i> , 2021, 13, 3046.	3.7	5
9	Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: A retrospective analysis of available scoring tools. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1778-1783.	1.0	5
10	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG/STS 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552.	4.1	2
11	Lung metastasectomy for osteosarcoma in children, adolescents, and young adults: proof of permanent cure. <i>Tumori</i> , 2021, , 030089162110530.	1.1	5
12	Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 1703-1713.	3.0	12
13	High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. <i>Cells</i> , 2020, 9, 2389.	4.1	22
14	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	1.6	145
15	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. <i>JAMA Oncology</i> , 2020, 6, 724.	7.1	139
16	Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS). <i>Scientific Reports</i> , 2020, 10, 10853.	3.3	10
17	Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10517-10517.	1.6	2
18	Fibroblastic/Myofibroblastic Tumors. , 2020, , 241-272.		0

#	ARTICLE	IF	CITATIONS
19	Osteosarcomas (OS)., 2020, , 185-212.		0
20	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Scientific Reports, 2019, 9, 12174.	3.3	52
21	Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients. Human Pathology, 2019, 91, 11-18.	2.0	20
22	Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation. Cell Death and Disease, 2019, 10, 471.	6.3	23
23	In situ cell cycle analysis in giant cell tumor of bone reveals patients with elevated risk of reduced progression-free survival. Bone, 2019, 127, 188-198.	2.9	13
24	Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 299-311.	3.3	16
25	Malignancy in Giant Cell Tumor of Bone: A Review of the Literature. Technology in Cancer Research and Treatment, 2019, 18, 153303381984000.	1.9	89
26	Unlocking bone for proteomic analysis and FISH. Laboratory Investigation, 2019, 99, 708-721.	3.7	5
27	Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 815-824.	2.8	53
28	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. European Journal of Cancer, 2018, 93, 28-36.	2.8	49
29	Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. Bone Marrow Transplantation, 2018, 53, 591-599.	2.4	8
30	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy. Clinical Cancer Research, 2018, 24, 3704-3716.	7.0	33
31	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori, 2018, 104, 30-36.	1.1	84
32	Genome-wide association study identifies the <i>GLDC</i> / <i>IL33</i> locus associated with survival of osteosarcoma patients. International Journal of Cancer, 2018, 142, 1594-1601.	5.1	31
33	Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. Expert Review of Molecular Diagnostics, 2018, 18, 947-961.	3.1	12
34	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncology, The, 2018, 19, 1360-1371.	10.7	61
35	A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular Cancer Therapeutics, 2018, 17, 1881-1892.	4.1	33
36	Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. Modern Pathology, 2018, 31, 1694-1707.	5.5	11

#	ARTICLE	IF	CITATIONS
37	Circulating Candidate Biomarkers in Giant Cell Tumors of Bone. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1800041.	1.6	5
38	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of IGF1R. <i>Frontiers in Endocrinology</i> , 2018, 9, 178.	3.5	37
39	Serum Antibodies Against Simian Virus 40 Large T Antigen, the Viral Oncoprotein, in Osteosarcoma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 64.	3.7	6
40	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. <i>Nature Communications</i> , 2018, 9, 3184.	12.8	50
41	Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 49-60.	1.9	31
42	Osteosarcoma follow-up: chest X-ray or computed tomography?. <i>Clinical Sarcoma Research</i> , 2017, 7, 3.	2.3	17
43	Fibrocartilaginous mesenchymoma of bone: a single institution experience with molecular investigations and a review of the literature. <i>Histopathology</i> , 2017, 71, 134-142.	2.9	11
44	Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?. <i>Future Oncology</i> , 2017, 13, 673-677.	2.4	23
45	Targeting ROCK2 rather than ROCK1 inhibits Ewing sarcoma malignancy. <i>Oncology Reports</i> , 2017, 37, 1387-1393.	2.6	12
46	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2017, 18, 812-822.	10.7	370
47	miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 77-88.	4.4	18
48	Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26650.	1.5	1
49	Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors. <i>Pathology Research and Practice</i> , 2017, 213, 1048-1053.	2.3	24
50	Soft Tissue Tumors Rarely Presenting Primary in Bone; Diagnostic Pitfalls. <i>Surgical Pathology Clinics</i> , 2017, 10, 705-730.	1.7	20
51	Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 245-257.	3.3	14
52	The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 215-223.	6.4	52
53	The distinct clinical features of giant cell tumor of bone in pagetic and non-pagetic patients are associated with genetic, biochemical and histological differences. <i>Oncotarget</i> , 2017, 8, 63121-63131.	1.8	15
54	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. <i>Oncotarget</i> , 2017, 8, 111836-111846.	1.8	44

#	ARTICLE	IF	CITATIONS
55	Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1 [®] can Overcome Drug Resistance in Osteosarcoma. Current Cancer Drug Targets, 2016, 16, 261-274.	1.6	47
56	Ewing Sarcoma in Patients over 40 Years of Age: A Prospective Analysis of 31 Patients Treated at a Single Institution. Tumori, 2016, 102, 481-487.	1.1	13
57	Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. Spine, 2016, 41, 1049-1057.	2.0	74
58	<i>CIC</i> – <i>DUX4</i> fusion–positive round-cell sarcomas of soft tissue and bone: a single-institution morphological and molecular analysis of seven cases. Histopathology, 2016, 69, 624-634.	2.9	73
59	Identification of novel candidate circulating biomarkers for malignant soft tissue sarcomas: Correlation with metastatic progression. Proteomics, 2016, 16, 689-697.	2.2	10
60	Telangiectatic osteosarcoma: a review of 87 cases. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2197-2207.	2.5	32
61	The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas. Pathology Research and Practice, 2016, 212, 811-816.	2.3	51
62	p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases. Human Pathology, 2016, 58, 15-23.	2.0	20
63	Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. Pharmacogenomics, 2016, 17, 2097-2114.	1.3	24
64	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Annals of Oncology, 2016, 27, 2283-2288.	1.2	90
65	Defining Ewing and Ewing-like small round cell tumors (SRCT): The need for molecular techniques in their categorization and differential diagnosis. A study of 200 cases. Annals of Diagnostic Pathology, 2016, 22, 25-32.	1.3	55
66	Design and construction of a new human naïve single-chain fragment variable antibody library, IORISS1. Journal of Biotechnology, 2016, 224, 1-11.	3.8	8
67	Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PLoS ONE, 2016, 11, e0166233.	2.5	31
68	Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget, 2016, 7, 61970-61987.	1.8	41
69	CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression. Oncotarget, 2016, 7, 77958-77967.	1.8	6
70	CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. Oncotarget, 2016, 7, 79925-79942.	1.8	40
71	Small Cell Osteosarcoma. American Journal of Surgical Pathology, 2015, 39, 691-699.	3.7	49
72	Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study. Journal of Orthopaedic Research, 2015, 33, 1205-1211.	2.3	27

#	ARTICLE	IF	CITATIONS
73	Fusion events lead to truncation of <i>FOS</i> in epithelioid hemangioma of bone. Genes Chromosomes and Cancer, 2015, 54, 565-574.	2.8	69
74	Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines. Frontiers in Endocrinology, 2015, 6, 74.	3.5	25
75	Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro-Oncology, 2015, 17, 63-69.	1.2	17
76	Advances in emerging drugs for osteosarcoma. Expert Opinion on Emerging Drugs, 2015, 20, 495-514.	2.4	82
77	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncology, The, 2015, 16, 98-107.	10.7	270
78	miR-196a expression in human and canine osteosarcomas: A comparative study. Research in Veterinary Science, 2015, 99, 112-119.	1.9	15
79	Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy. Histopathology, 2015, 67, 338-347.	2.9	24
80	Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response?. Orphanet Journal of Rare Diseases, 2015, 10, 6.	2.7	28
81	A Genome-Wide Scan Identifies Variants in <i>NFIB</i> Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	9.4	88
82	Significant association between human osteosarcoma and simian virus 40. Cancer, 2015, 121, 708-715.	4.1	22
83	MDM2 and CDK4 expression in periosteal osteosarcoma. Human Pathology, 2015, 46, 549-553.	2.0	34
84	Primary pseudomyogenic haemangioendothelioma of bone: report of two cases. Skeletal Radiology, 2015, 44, 727-731.	2.0	31
85	Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents. Clinical Cancer Research, 2015, 21, 1373-1382.	7.0	39
86	CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin. Clinical Cancer Research, 2015, 21, 146-156.	7.0	42
87	Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. Journal of Clinical Oncology, 2015, 33, 3628-3634.	1.6	59
88	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. Journal of Clinical Oncology, 2015, 33, 3036-3046.	1.6	516
89	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. European Journal of Cancer, 2015, 51, 210-217.	2.8	97
90	Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma. American Journal of Cancer Research, 2015, 5, 3446-54.	1.4	14

#	ARTICLE	IF	CITATIONS
91	Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis. PLoS ONE, 2014, 9, e107105.	2.5	15
92	p53-Dependent Activation of microRNA-34a in Response to Etoposide-Induced DNA Damage in Osteosarcoma Cell Lines Not Impaired by Dominant Negative p53 Expression. PLoS ONE, 2014, 9, e114757.	2.5	35
93	The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation. PLoS Genetics, 2014, 10, e1004475.	3.5	335
94	Sequencing IDH1/2 glioma mutation hotspots in gliomas and malignant peripheral nerve sheath tumors. Neuro-Oncology, 2014, 16, 320-322.	1.2	5
95	Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Investigational New Drugs, 2014, 32, 1167-1180.	2.6	28
96	Copy number alterations and neoplasia-specific mutations in <i>MELK</i> , <i>PDCD1LG2</i> , <i>TLN1</i> , and <i>PAX5</i> at 9p in different neoplasias. Genes Chromosomes and Cancer, 2014, 53, 579-588.	2.8	14
97	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
98	Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer, 2014, 120, 3159-3164.	4.1	83
99	CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2. Journal of Bone and Mineral Research, 2014, 29, 1295-1309.	2.8	37
100	Surgical treatment and results of 62 patients with epithelioid hemangioendothelioma of bone. Journal of Surgical Oncology, 2014, 109, 791-797.	1.7	35
101	Primary Angiosarcoma of Bone. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 528-534.	1.3	34
102	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. Molecular Cancer Therapeutics, 2014, 13, 249-259.	4.1	30
103	Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma. Cancer Research, 2014, 74, 6578-6588.	0.9	66
104	Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. Clinical and Experimental Metastasis, 2014, 31, 15-24.	3.3	20
105	Difficulty distinguishing benign notochordal cell tumor from chordoma further suggests a link between them. Cancer Imaging, 2014, 14, 4.	2.8	42
106	An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer, 2014, 14, 137.	2.6	13
107	Immunoreactivity using anti-ERG monoclonal antibodies in sarcomas is influenced by clone selection. Pathology Research and Practice, 2014, 210, 508-513.	2.3	14
108	Diagnostic Utility of Molecular Investigation in Extraskelatal Myxoid Chondrosarcoma. Journal of Molecular Diagnostics, 2014, 16, 314-323.	2.8	26

#	ARTICLE	IF	CITATIONS
109	Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation. <i>Oncology Reports</i> , 2014, 31, 370-375.	2.6	27
110	Classic Osteosarcoma. , 2014, , 147-152.		19
111	Secondary Osteosarcoma. , 2014, , 157-158.		1
112	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISC/OS-Oss). <i>Tumori</i> , 2014, 100, 612-619.	1.1	17
113	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISC/OS-Oss). <i>Tumori</i> , 2014, 100, 612-9.	1.1	17
114	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. <i>Clinical Cancer Research</i> , 2013, 19, 2117-2131.	7.0	96
115	Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients's bed. <i>Journal of Translational Medicine</i> , 2013, 11, 268.	4.4	115
116	Genome-wide association study identifies two susceptibility loci for osteosarcoma. <i>Nature Genetics</i> , 2013, 45, 799-803.	21.4	181
117	Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 109-120.	2.8	24
118	Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGF β 2 as Potential Targets. <i>American Journal of Pathology</i> , 2013, 182, 1347-1356.	3.8	53
119	Enchondroma vs. chondrosarcoma: A simple, easy-to-use, new magnetic resonance sign. <i>European Journal of Radiology</i> , 2013, 82, 2154-2160.	2.6	30
120	Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 665-671.	2.8	18
121	miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control. <i>International Journal of Oncology</i> , 2013, 42, 667-675.	3.3	106
122	NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion. <i>Journal of Molecular Cell Biology</i> , 2013, 5, 176-193.	3.3	55
123	Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. <i>Neuro-Oncology</i> , 2013, 15, 135-147.	1.2	190
124	Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 2473-2485.	7.0	31
125	Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 2303-2312.	1.6	161
126	Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug. <i>PLoS ONE</i> , 2013, 8, e83832.	2.5	43

#	ARTICLE	IF	CITATIONS
127	MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone. <i>Histology and Histopathology</i> , 2013, 28, 671-8.	0.7	28
128	Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing's Sarcoma Tumor Cells. <i>Current Pharmaceutical Biotechnology</i> , 2013, 14, 449-463.	1.6	18
129	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 850-856.	1.6	156
130	Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma. <i>Molecular Endocrinology</i> , 2012, 26, 1603-1616.	3.7	53
131	Osteosarcoma of the Mobile Spine. <i>Spine</i> , 2012, 37, E381-E386.	2.0	60
132	Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 333-337.	2.8	21
133	Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. <i>Molecular BioSystems</i> , 2012, 8, 994-1006.	2.9	69
134	Vascular bone tumors: a proposal of a classification based on clinicopathological, radiographic and genetic features. <i>Skeletal Radiology</i> , 2012, 41, 1495-1507.	2.0	57
135	Osteosarcoma of the Pelvis: A Monoinstitutional Experience in Patients Younger than 41 Years. <i>Tumori</i> , 2012, 98, 702-708.	1.1	17
136	miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemosensitivity and malignancy. <i>Journal of Pathology</i> , 2012, 226, 796-805.	4.5	128
137	Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1. <i>Journal of Clinical Oncology</i> , 2012, 30, 2112-2118.	1.6	165
138	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. <i>Annals of Oncology</i> , 2012, 23, 508-516.	1.2	296
139	Clinical outcome of central conventional chondrosarcoma. <i>Journal of Surgical Oncology</i> , 2012, 106, 929-937.	1.7	160
140	Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 899-909.	2.8	95
141	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. <i>Nature Genetics</i> , 2012, 44, 323-327.	21.4	160
142	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	4.1	85
143	Receptor tyrosine kinase pathway analysis sheds light on similarities between clear cell sarcoma and metastatic melanoma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 111-126.	2.8	22
144	Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples. <i>BioTechniques</i> , 2012, 0, 1-7.	1.8	27

#	ARTICLE	IF	CITATIONS
145	Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years. Tumori, 2012, 98, 702-8.	1.1	8
146	Molecular Diagnosis in Ewing Family Tumors. Journal of Molecular Diagnostics, 2011, 13, 313-324.	2.8	70
147	Clinical Significance of Tumor Protein D52 Immunostaining in a Large Series of Ewing's Sarcoma Family of Tumors. Pediatric and Developmental Pathology, 2011, 14, 255-256.	1.0	4
148	Identification of Potential Biomarkers for Giant Cell Tumor of Bone Using Comparative Proteomics Analysis. American Journal of Pathology, 2011, 178, 88-97.	3.8	41
149	Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. European Journal of Cancer, 2011, 47, 1258-1266.	2.8	49
150	Late sarcoma development after curettage and bone grafting of benign bone tumors. European Journal of Radiology, 2011, 77, 19-25.	2.6	23
151	Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy. Analytical Cellular Pathology, 2011, 34, 131-145.	1.4	20
152	Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. Histopathology, 2011, 59, 376-389.	2.9	20
153	Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene, 2011, 30, 2730-2740.	5.9	119
154	Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Annals of Oncology, 2011, 22, 1221-1227.	1.2	107
155	Epithelial marker expression does not rule out a diagnosis of Ewing's sarcoma family of tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 409-414.	2.8	22
156	Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. Genes Chromosomes and Cancer, 2011, 50, 291-306.	2.8	22
157	The t(X;6) in subungual exostosis results in transcriptional deregulation of the gene for insulin receptor substrate 4. International Journal of Cancer, 2011, 128, 487-491.	5.1	37
158	Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors. International Journal of Cancer, 2011, 128, 1139-1150.	5.1	51
159	Palliative therapy for osteosarcoma. Expert Review of Anticancer Therapy, 2011, 11, 217-227.	2.4	58
160	Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. Analytical Cellular Pathology, 2011, 34, 131-45.	1.4	17
161	High Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients. ISRN Oncology, 2011, 2011, 1-10.	2.1	71
162	Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers. Annals of Surgical Oncology, 2010, 17, 211-219.	1.5	159

#	ARTICLE	IF	CITATIONS
163	Response to the letter by Dr Klein. Skeletal Radiology, 2010, 39, 71-71.	2.0	0
164	Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer, 2010, 10, 462.	2.6	119
165	Frequent deletion of <i>CDKN2A</i> and recurrent coamplification of <i>KIT</i> , <i>PDGFRA</i> , and <i>KDR</i> in fibrosarcoma of bone—An array comparative genomic hybridization study. Genes Chromosomes and Cancer, 2010, 49, 132-143.	2.8	16
166	Biological indicators of prognosis in Ewing's sarcoma: An emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). International Journal of Cancer, 2010, 126, 41-52.	5.1	31
167	Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases. Histopathology, 2010, 57, 59-72.	2.9	22
168	Vincristine, Doxorubicin, Cyclophosphamide, Actinomycin D, Ifosfamide, and Etoposide in Adult and Pediatric Patients with Nonmetastatic Ewing Sarcoma. Final Results of a Monoinstitutional Study. Tumori, 2010, 96, 213-218.	1.1	15
169	Xg Expression in Ewing's Sarcoma Is of Prognostic Value and Contributes to Tumor Invasiveness. Cancer Research, 2010, 70, 3730-3738.	0.9	21
170	NVP-BEZ235 as a New Therapeutic Option for Sarcomas. Clinical Cancer Research, 2010, 16, 530-540.	7.0	142
171	Centrosome abnormalities in giant cell tumour of bone: possible association with chromosomal instability. Modern Pathology, 2010, 23, 359-366.	5.5	23
172	Emerging drugs for high-grade osteosarcoma. Expert Opinion on Emerging Drugs, 2010, 15, 615-634.	2.4	92
173	CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. Journal of Clinical Investigation, 2010, 120, 668-680.	8.2	150
174	Prognostic Relevance of CCN3 in Bone Sarcomas. , 2010, , 223-243.		0
175	Overcoming Resistance to Conventional Drugs in Ewing Sarcoma and Identification of Molecular Predictors of Outcome. Journal of Clinical Oncology, 2009, 27, 2209-2216.	1.6	121
176	Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics, 2009, 10, 625.	2.8	228
177	Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer, 2009, 9, 17.	2.6	57
178	Synovial sarcoma. Cancer, 2009, 115, 2988-2998.	4.1	156
179	Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes and Cancer, 2009, 48, 289-309.	2.8	46
180	NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. Journal of Orthopaedic Research, 2009, 27, 135-140.	2.3	45

#	ARTICLE	IF	CITATIONS
181	Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 455, 397-411.	2.8	181
182	Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival. <i>Clinical Cancer Research</i> , 2009, 15, 3550-3556.	7.0	62
183	Prognostic relevance of CCN3 in Ewing sarcoma. <i>Human Pathology</i> , 2009, 40, 1479-1486.	2.0	32
184	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. <i>Molecular Cancer</i> , 2009, 8, 118.	19.2	159
185	The Treatment of Nonmetastatic High Grade Osteosarcoma of the Extremity: Review of the Italian Rizzoli Experience. Impact on the Future. <i>Cancer Treatment and Research</i> , 2009, 152, 275-287.	0.5	37
186	Overcoming Glutathione S-Transferase P1-Related Cisplatin Resistance in Osteosarcoma. <i>Cancer Research</i> , 2008, 68, 6661-6668.	0.9	113
187	Prognostic Value of CCN3 in Osteosarcoma. <i>Clinical Cancer Research</i> , 2008, 14, 701-709.	7.0	58
188	Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities in Preadolescent Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 908-912.	0.6	35
189	Targeting insulin-like growth factor 1 receptor in sarcomas. <i>Current Opinion in Oncology</i> , 2008, 20, 419-427.	2.4	94
190	Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2007, 78, 377-384.	3.3	30
191	Prognostic Value of P-Glycoprotein in High-Grade Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4858-4860.	1.6	14
192	Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling. <i>Cancer Research</i> , 2007, 67, 7675-7685.	0.9	81
193	Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma. <i>Clinical Cancer Research</i> , 2007, 13, 1322-1330.	7.0	126
194	Predictive Factors of Histologic Response to Primary Chemotherapy in Patients With Ewing Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 364-368.	0.6	29
195	Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. <i>Cancer Letters</i> , 2007, 250, 194-205.	7.2	43
196	Osteosarcoma: What did we learn from the paediatric experience for adolescents and young adults?. <i>European Journal of Cancer</i> , Supplement, 2007, 5, 227-234.	2.2	3
197	Osteosarcoma (Osteogenic sarcoma). <i>Orphanet Journal of Rare Diseases</i> , 2007, 2, 6.	2.7	364
198	Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60. <i>Cancer</i> , 2007, 109, 780-786.	4.1	62

#	ARTICLE	IF	CITATIONS
199	Local recurrence and local control of non-metastatic osteosarcoma of the extremities: A 27-year experience in a single institution. <i>Journal of Surgical Oncology</i> , 2007, 96, 118-123.	1.7	126
200	Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 505-511.	0.8	19
201	Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy The Rizzoli experience in 52 patients. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2006, 77, 938-943.	3.3	49
202	Î±-Tocopheryl succinate alters cell cycle distribution sensitising human osteosarcoma cells to methotrexate-induced apoptosis. <i>Cancer Letters</i> , 2006, 232, 226-235.	7.2	31
203	Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing's sarcoma. <i>European Journal of Cancer</i> , 2006, 42, 91-96.	2.8	69
204	Malignant fibrous histiocytoma of bone: Analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. <i>European Journal of Cancer</i> , 2006, 42, 1172-1180.	2.8	42
205	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. <i>International Journal of Oncology</i> , 2006, 29, 1459.	3.3	19
206	Second Malignant Neoplasm in Patients With Osteosarcoma of the Extremities Treated With Adjuvant and Neoadjuvant Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 774-780.	0.6	38
207	Chordoma of the Mobile Spine: Fifty Years of Experience. <i>Spine</i> , 2006, 31, 493-503.	2.0	358
208	No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. <i>Anti-Cancer Drugs</i> , 2006, 17, 411-415.	1.4	14
209	The role of surgical margins in treatment of Ewing's sarcoma family tumors: Experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 766-772.	0.8	92
210	Histologically verified lung metastases in benign giant cell tumours: 14 cases from a single institution. <i>International Orthopaedics</i> , 2006, 30, 499-504.	1.9	124
211	Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. <i>Cancer</i> , 2006, 106, 1154-1161.	4.1	502
212	Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. <i>International Journal of Cancer</i> , 2006, 119, 1039-1046.	5.1	49
213	CD99 Acts as an Oncosuppressor in Osteosarcoma. <i>Molecular Biology of the Cell</i> , 2006, 17, 1910-1921.	2.1	60
214	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. <i>International Journal of Oncology</i> , 2006, 29, 1459-68.	3.3	20
215	Adjuvant chemotherapy for soft tissue sarcoma. <i>Current Opinion in Oncology</i> , 2005, 17, 361-365.	2.4	26
216	Primary High-Grade Osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 129-134.	0.6	42

#	ARTICLE	IF	CITATIONS
217	Second Malignancy in 597 Patients With Ewing Sarcoma of Bone Treated at a Single Institution With Adjuvant and Neoadjuvant Chemotherapy Between 1972 and 1999. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 517-520.	0.6	49
218	In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. <i>Oncogene</i> , 2005, 24, 4349-4361.	5.9	90
219	Evaluation of the molecular mechanisms involved in the gain of function of a Li-FraumeniTP53 Mutation. <i>Human Mutation</i> , 2005, 26, 94-103.	2.5	12
220	Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2005, 23, 8845-8852.	1.6	394
221	Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors. <i>Cancer Research</i> , 2005, 65, 3868-3876.	0.9	272
222	Î±-Tocopheryl succinate induces cytostasis and apoptosis in osteosarcoma cells: the role of E2F1. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 1515-1521.	2.1	25
223	Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. <i>European Journal of Cancer</i> , 2005, 41, 1349-1361.	2.8	123
224	Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. <i>European Journal of Cancer</i> , 2005, 41, 2079-2085.	2.8	115
225	4-Demethoxy-3-aziridinyl-4-methylsulphonyl-daunorubicin (PNU-159548): A promising new candidate for chemotherapeutic treatment of osteosarcoma patients. <i>European Journal of Cancer</i> , 2005, 41, 2184-2195.	2.8	9
226	Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. <i>European Journal of Cancer</i> , 2005, 41, 2836-2845.	2.8	127
227	Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. <i>Acta Oncologica</i> , 2005, 44, 748-755.	1.8	124
228	Comparison of the Outcome of Conventional Osteosarcoma at Two Specialist International Orthopaedic Oncology Centres. <i>Sarcoma</i> , 2004, 8, 13-18.	1.3	18
229	Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. <i>Oncogene</i> , 2004, 23, 5664-5674.	5.9	108
230	Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone. <i>European Journal of Cell Biology</i> , 2004, 83, 483-491.	3.6	22
231	Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. <i>International Journal of Cancer</i> , 2004, 108, 358-366.	5.1	61
232	Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. <i>Bone</i> , 2004, 34, 672-679.	2.9	33
233	Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma Findings in 42 patients followed for 1-16 years. <i>Acta Orthopaedica</i> , 2004, 75, 487-491.	1.4	49
234	Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. <i>European Journal of Cell Biology</i> , 2003, 82, 483-493.	3.6	36

#	ARTICLE	IF	CITATIONS
235	Platelet-derived growth factors enhance proliferation of human stromal stem cells. <i>Biomaterials</i> , 2003, 24, 3095-3100.	11.4	351
236	Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival. <i>Journal of Clinical Oncology</i> , 2003, 21, 710-715.	1.6	277
237	c-kit Receptor Expression in Ewing's Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate Conditions. <i>Journal of Clinical Oncology</i> , 2003, 21, 1952-1960.	1.6	71
238	Value of P-Glycoprotein and Clinicopathologic Factors as the Basis for New Treatment Strategies in High-Grade Osteosarcoma of the Extremities. <i>Journal of Clinical Oncology</i> , 2003, 21, 536-542.	1.6	95
239	Identification of markers of possible prognostic value in 57 giant cell tumors of bone. <i>Oncology Reports</i> , 2003, 10, 351-6.	2.6	31
240	The Expression of ccn3(nov) Gene in Musculoskeletal Tumors. <i>American Journal of Pathology</i> , 2002, 160, 849-859.	3.8	99
241	Troglitazone affects survival of human osteosarcoma cells. <i>International Journal of Cancer</i> , 2002, 98, 344-351.	5.1	30
242	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. <i>International Journal of Cancer</i> , 2002, 101, 11-16.	5.1	96
243	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. <i>Cancer Gene Therapy</i> , 2002, 9, 296-307.	4.6	101
244	Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. <i>Clinical Cancer Research</i> , 2002, 8, 3893-903.	7.0	39
245	Histologic Response of High-Grade Nonmetastatic Osteosarcoma of the Extremity to Chemotherapy. <i>Clinical Orthopaedics and Related Research</i> , 2001, 386, 186-196.	1.5	48
246	Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. <i>Annals of Oncology</i> , 2001, 12, 1145-1150.	1.2	138
247	Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 1238-1247.	1.6	631
248	Aneurysmal Bone Cyst of the Mobile Spine. <i>Spine</i> , 2001, 26, 27-35.	2.0	256
249	Radiological features of 24 periosteal chondrosarcomas. <i>Skeletal Radiology</i> , 2001, 30, 208-212.	2.0	43
250	Radiological study of 12 high-grade surface osteosarcomas. <i>Skeletal Radiology</i> , 2001, 30, 667-671.	2.0	26
251	Involvement ofINK4A gene products in the pathogenesis and development of human osteosarcoma. <i>Cancer</i> , 2001, 92, 3062-3067.	4.1	47
252	DNA copy number amplifications in sarcomas with homogeneously staining regions and double minutes. <i>Cytometry</i> , 2001, 46, 79-84.	1.8	12

#	ARTICLE	IF	CITATIONS
253	Changes in p14ARF do not play a primary role in human chondrosarcoma tissues. International Journal of Cancer, 2001, 93, 703-705.	5.1	8
254	Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report. Journal of Clinical Oncology, 2000, 18, 4016-4027.	1.6	385
255	Prognostic Significance of Nuclear Accumulation of c-myc and mdm2 Proteins in Synovial Sarcoma of the Extremities. Oncology, 2000, 58, 253-260.	1.9	15
256	Massive Bone Allograft Reconstruction in High-Grade Osteosarcoma. Clinical Orthopaedics and Related Research, 2000, 377, 186-194.	1.5	180
257	Analysis of 12q13-15 Genes in Parosteal Osteosarcoma. Clinical Orthopaedics and Related Research, 2000, 377, 195-204.	1.5	45
258	Chondrosarcoma of the Mobile Spine. Spine, 2000, 25, 804-812.	2.0	220
259	Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. , 2000, 85, 782-786.		63
260	Malignant fibrous histiocytoma: Inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21-22?evidence for a common genetic defect. Genes Chromosomes and Cancer, 2000, 27, 191-195.	2.8	36
261	Presence and expression of the Simian virus-40 genome in human giant cell tumors of bone. , 2000, 28, 23-30.		16
262	Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone. International Journal of Cancer, 2000, 87, 328-335.	5.1	21
263	Murine model for skeletal metastases of Ewing's sarcoma. Journal of Orthopaedic Research, 2000, 18, 959-966.	2.3	22
264	Prognostic Factors in Nonmetastatic Ewing's Sarcoma of Bone Treated With Adjuvant Chemotherapy: Analysis of 359 Patients at the Istituto Ortopedico Rizzoli. Journal of Clinical Oncology, 2000, 18, 4-4.	1.6	309
265	Increased C-MYC Oncogene Expression in Ewing's Sarcoma: Correlation with Ki67 Proliferation Index. Tumori, 1999, 85, 167-173.	1.1	39
266	Nonmetastatic Osteosarcoma of the Extremity: Results of a Neoadjuvant Chemotherapy Protocol (IOR/OS-3) with High-dose Methotrexate, Intraarterial or Intravenous Cisplatin, Doxorubicin, and Salvage Chemotherapy Based on Histologic Tumor Response. Tumori, 1999, 85, 458-464.	1.1	71
267	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 1999, 18, 739-746.	5.9	35
268	Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone. Cancer, 1999, 86, 421-428.	4.1	155
269	Redundancy of autocrine loops in human osteosarcoma cells. , 1999, 80, 581-588.		78
270	Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. , 1999, 84, 489-493.		93

#	ARTICLE	IF	CITATIONS
271	Staging and treatment of primary tumors of the spine. <i>Current Opinion in Orthopaedics</i> , 1999, 10, 93-100.	0.3	3
272	Correlation between Apoptosis and TP53 Status in Osteosarcoma. <i>Cancer Genetics and Cytogenetics</i> , 1998, 105, 177-181.	1.0	6
273	Neoadjuvant chemotherapy for Ewing's sarcoma of bone. , 1998, 82, 1174-1183.		68
274	Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1998, 23, 213-219.	2.8	44
275	Prognostic relevance of C-mycgene expression in giant-cell tumor of bone. <i>Journal of Orthopaedic Research</i> , 1998, 16, 1-7.	2.3	38
276	Osteosarcoma of the Bones of the Foot – an Easily Misdiagnosed Malignant Tumor. <i>Mayo Clinic Proceedings</i> , 1998, 73, 842-847.	3.0	88
277	Predictive factors for local recurrence in osteosarcoma 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. <i>Acta Orthopaedica</i> , 1998, 69, 230-236.	1.4	134
278	<i>C-myc</i> and <i>c-fos</i> in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression. <i>Oncology</i> , 1998, 55, 556-563.	1.9	182
279	Neoadjuvant Chemotherapy for Extremity Osteosarcoma: Preliminary Results of the Rizzoli's 4th Study. <i>Acta Oncol&sup3gica</i> , 1998, 37, 41-48.	1.8	78
280	Predictive Factors of Histological Response to Primary Chemotherapy in Ewing's Sarcoma. <i>Acta Oncol&sup3gica</i> , 1998, 37, 671-676.	1.8	19
281	Neoadjuvant Chemotherapy for High Grade Malignant Fibrous Histiocytoma of Bone. <i>Clinical Orthopaedics and Related Research</i> , 1998, 346, 178-189.	1.5	12
282	Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 1997, 8, 765-771.	1.2	100
283	Altered G1 phase regulation in osteosarcoma. , 1997, 74, 518-522.		29
284	Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. <i>Human Pathology</i> , 1996, 27, 408-416.	2.0	94
285	Oncogene alterations in primary, recurrent, and metastatic human bone tumors. <i>Journal of Cellular Biochemistry</i> , 1996, 63, 37-50.	2.6	91
286	Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome. <i>New England Journal of Medicine</i> , 1995, 333, 1380-1385.	27.0	372
287	Treatment Recommendations for Osteosarcoma and Adult Soft Tissue Sarcomas. <i>Drugs</i> , 1994, 47, 82-92.	10.9	36
288	Osteosarcoma. Low-grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. <i>Cancer</i> , 1993, 71, 338-345.	4.1	123

#	ARTICLE	IF	CITATIONS
289	Solid variant of aneurysmal bone cyst. Cancer, 1993, 71, 729-734.	4.1	121
290	Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer, 1993, 71, 1224-1230.	4.1	99
291	Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer, 1993, 72, 3227-3238.	4.1	285
292	Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAP-35). International Journal of Cell Cloning, 1990, 8, 409-424.	1.6	25
293	Case report 629. Skeletal Radiology, 1990, 19, 461-464.	2.0	6
294	Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities the istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer, 1990, 65, 2539-2553.	4.1	230
295	Primary Chemotherapy and Delayed Surgery for Malignant Fibrous Histiocytoma of Bone in the Extremity. Tumori, 1990, 76, 537-542.	1.1	11
296	Case report 489. Skeletal Radiology, 1988, 17, 432-435.	2.0	19
297	Case report 489. Skeletal Radiology, 1988, 17, 315-316.	2.0	0
298	Metastatic Patterns in Osteosarcoma. Tumori, 1988, 74, 421-427.	1.1	52
299	Prognostic Value of Serum Alkaline Phosphatase in Osteosarcoma. Tumori, 1987, 73, 331-336.	1.1	22
300	Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. European Journal of Cancer & Clinical Oncology, 1986, 22, 1337-1345.	0.7	61
301	Therapy for primary non-Hodgkin's lymphoma of bone and a comparison of results with ewing's sarcoma. Ten years' experience at the Istituto Ortopedico Rizzoli. Cancer, 1986, 57, 1468-1472.	4.1	53
302	Osteoid osteoma and osteoblastoma of the talus. Skeletal Radiology, 1986, 15, 360-364.	2.0	74
303	Giant cell reparative granuloma and other giant cell lesions of the bones of the hands and feet. Skeletal Radiology, 1986, 15, 415-421.	2.0	59
304	Case Report 301. Skeletal Radiology, 1985, 13, 94-95.	2.0	0
305	Case report 301. Skeletal Radiology, 1985, 13, 228-232.	2.0	6
306	Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor. Cancer, 1985, 56, 1515-1521.	4.1	260

#	ARTICLE	IF	CITATIONS
307	Staging, Therapy and Prognosis of Primary Non-Hodgkin's Lymphoma of Bone and a Comparison of Results with Localized Ewing's Sarcoma: Ten Years Experience at the Istituto Ortopedico Rizzoli. Tumori, 1985, 71, 345-354.	1.1	7
308	Localized Ewing's sarcoma of bone: Ten years' experience at the Istituto Ortopedico Rizzoli in 124 cases treated with multimodal therapy. European Journal of Cancer & Clinical Oncology, 1985, 21, 163-173.	0.7	63
309	Intracortical osteosarcoma: Rare entity or early manifestation of classical osteosarcoma?. Skeletal Radiology, 1983, 9, 255-258.	2.0	27
310	Mesenchymal chondrosarcoma of bone and soft tissues. Cancer, 1983, 52, 533-541.	4.1	132
311	Full-lung tomograms and bone scanning in the initial work-up of patients with osteogenic sarcoma. A review of 126 cases. European Journal of Cancer & Clinical Oncology, 1982, 18, 967-971.	0.7	16
312	The treatment of localized Ewing's sarcoma: The experience at the istituto ortopedico rizzoli in 163 cases treated with and without adjuvant chemotherapy. Cancer, 1982, 49, 1561-1570.	4.1	75
313	The treatment of osteosarcoma of the extremities: Twenty year's experience at the istituto ortopedico rizzoli. Cancer, 1981, 48, 1569-1581.	4.1	147
314	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. , 0, .		1